ACIM
NBIX icon

Azimuth Capital Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Azimuth Capital Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19M Sell
112,466
-9,238
-8% -$1.37M 0.64% 47
2026
Q1 		$16M Sell
121,704
-574
-0.5% -$76.2K 0.6% 50
2025
Q4 		$17.3M Buy
122,278
+51,600
+73% +$7.48M 0.62% 42
2025
Q3 		$9.92M Sell
70,678
-1,319
-2% -$179K 0.36% 93
2025
Q2 		$9.05M Sell
71,997
-7,321
-9% -$840K 0.34% 109
2025
Q1 		$8.77M Sell
79,318
-35,990
-31% -$4.56M 0.35% 102
2024
Q4 		$15.7M Sell
115,308
-71
-0.1% -$8.78K 0.61% 49
2024
Q3 		$13.3M Buy
115,379
+48,973
+74% +$6.71M 0.52% 54
2024
Q2 		$9.14M Buy
66,406
+1,867
+3% +$256K 0.37% 87
2024
Q1 		$8.9M Buy
+64,539
New +$8.81M 0.37% 92

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Azimuth Capital Investment Management's NBIX Position: Q2 2026 in Review

Azimuth Capital Investment Management reduced its Neurocrine Biosciences (NBIX) stake by 7.6% in Q2 2026, selling an estimated $1.37M and leaving 112,466 shares worth $19M. The position accounts for 0.64% of the portfolio, ranked #47.

Azimuth Capital Investment Management first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Azimuth Capital Investment Management held 112,466 shares of Neurocrine Biosciences worth $19M as of Q2 2026.
  • Azimuth Capital Investment Management sold 9,238 Neurocrine Biosciences shares in Q2 2026, an estimated $1.37M.
  • Neurocrine Biosciences made up 0.64% of Azimuth Capital Investment Management's portfolio in Q2 2026, its #47 holding.
  • Azimuth Capital Investment Management first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Azimuth Capital Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.